HUE029808T2 - Szubsztituált acilanilid-származékok és az alkalmazásukra szolgáló eljárások - Google Patents
Szubsztituált acilanilid-származékok és az alkalmazásukra szolgáló eljárások Download PDFInfo
- Publication number
- HUE029808T2 HUE029808T2 HUE07837277A HUE07837277A HUE029808T2 HU E029808 T2 HUE029808 T2 HU E029808T2 HU E07837277 A HUE07837277 A HU E07837277A HU E07837277 A HUE07837277 A HU E07837277A HU E029808 T2 HUE029808 T2 HU E029808T2
- Authority
- HU
- Hungary
- Prior art keywords
- agent
- treating
- compound
- disease
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
- C07C255/51—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings containing at least two cyano groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (7)
- Szabadalmi igénypontok L (1) képied: vég} ölesvap optikai izmnéi|e, vagy ezek égy gyógyászatiiag élfegadhato sója, vagy ezek tetszólegeskömkíaácii^a, 2, léömpözfelö, amely magában foglalja a*: b íg^ypönt ázerinii vefyüteígt vagy sóját vagy ezek kötfipl*-:pSelójáb#'«0-gyói>^^ilág eiíogadh&tó hordott, MgÄi :3, ä X igénypont szerinti kompozíció, atndy járulékosa» tartalmaz egy terápiás ágenst, .mely egy rák ellesi szer, egy mmmnmódiíláió szer. egy cukorbetegség kezelésére alkalmas: szer, egy idegrendszer kezelésére alkalmas szsb ep inrdlovaszkuláris rendszer kezelésére alkaipfós szer, egy gyomor-bélrendszer kezelésére ab kaltnas szar, égy dénnatológiai megbetegedés vagy kóros állaptvkezeÜsérá-apsteas saer, egy fertőzés elleni szer, egy máj kezelésére alkalmas szer, egy vese kezelésére alkalmas szer, egy anyagcsere-betegség kezelésén* alkalmas szer, egy sorvadásos hidegség kezelésére alkalmas szer, egy géntebtpiás szer, egy endokrin rendszer kezelésére alkalmas szer, egy vitamin,; egy; sztomatognaiíkom (a száj és az állkapcsok egykttesebkezéléséré alkalmas szer, egy hngy-ivmvervi szer,egy viselkedési hetbíyásoíó szer,ep iégzöszervrendszet kezelésére ab kaltnss szer, egy vérrenászér kezdésére alkalmas szer, egy szenlbeiepeg kezelésére alkalmas szer vagy ezek tetszőleges kombináotój a,
- 4. Ä g, Igénypönt ssÄtt készítmény, ahol a terápiás ágens egy anti-androgén, antsösztregén, egy moRokíoPális antitest, egy kemöÉnágías szer, egy immnnoszitppressziv vagy gyulladás ellent szer, egy ímmtaio-siimtdáns szer, egy megiittnid, inzulin, hlguanid, inhibitor, egy adrenomimetíkum, egy adrenoceptor antagonist«, egy kolmamlmetikus szer, egy rntiszkarinblokkoló, egy ganglíönbiokkoió. egy a|tatószer, egy Ihjdalsnuisillapito szer,egy osurotnuszkuláris transzmisszió kezelésére ab kalmas szer. egy idegrendszen sómaíátts, ep nyugíatóss^r, egy ueunxiegeneratív megbetedés kezelésére ab kaimas szer, egy aníiéprSéptíknm; egy atttlpziebetikum, ep kóros függőség elleni szer, egy aniiarrittnlkam, egy antiartginális s/er, egy vazoaktiv szenegy Mleiumesatorna blokkoló, egy magas vérnyomás ellem szeíj egy dktretikunt, egy antikoaguians vagy fibönolliikus szer, alacsony vérfc&l#pgæri»szi«t fc|^l##PöÉMmáá sszer,, egy opiöld, egy >-H Ts receptor antögonisita, egy adszorbsns, egy töltőanyag:, egy s?iMiÖ|^í#:V^::lá^áívtjní,. égy hssbnjíó szer, egy hányás ellem szer, egy savfcözömbtMÖ szeg egy %-reeypíor antagonista,, ép protonpumpa inhibitor, egy 5-amutoszaiiciku szer, égy proszisglándin, egy gíükokortSkoszteroid. egy MiSöid, égy fótokemoíerápiás szer. ep iótodinamikus szer, aminolévnlinsav, dapszon. pireirin, egy piretroíd, táiMomld, egy malária elleni szer, egy aníimikfobiáiis szer, egy aóiiiihgiís szer, egy amivirális szer, egy sztÄnanild, egy binietopfim szer, ép kínaion szer,: egy oxazoiidmon szef,égy aabszeptíkum:, egy Ma-ialíám:: szer, sp átnÍnógííikózid szer, ep tetraeikítO: szer, égy klôramibnikôl szer, egy makro! idi : szer, ep Imkozttrmrf szepap báejbamrtszíír, agy giilkopeptíd széiyep poíimixln szög ep protozoa elleni szerpep^^^hajiifi^jfkprtisspft, kolkiztn, metötmsät, ttrzotlezoxíkoisav, pnatelllamin* Hániuntltidroglnknrbönák egy biszioszlötíát, biotin, ailopurinol, íevodöpa, diazepam, ienobathííál, haloperídoi, feisav, haptoglobin, karolitn, ep sztemid, egy kannabtnoid, tnetoklopramki, eizapitk töedrokipmgesztetOn-aéetáí, inégésztróbacetát, éjprobéptádm, btdrazim sssîÂ, peiüoxtliHin, mhífeííiorofe» eikozapentémay, ittdptttÄeifo jbuproférty. melaiottm, inznli«, növekedési iteaiötij kMM; hasnyáknirigy-extrakíum, kabergolin, brómkriptin. tiroxím egy gonadotropin, egy glükokoitikoid analóg, kortikotroftn, nietirapon, amittögiutetirmd, mitotán, keiokonazoi, íRííspftotön, dexanteísrzon, egy szomaíosziatin analóg, egy gonadotropint folsgabádítd hormon analóg, fouprolíd; gozerelin, antidifoerikns hormon, itbxmöjßiÄlög, oxítoeín, egy öszttogén, egy progesztm, egy szelektív ösztrogén receptor modulátor ÍSJ-RM), «y,y méh stümiidttSs egy méh reiaxáns, egy ;«id-rögén, egy asttiastdrogétpegy proasagiatidfo, egy doparain receptor agonista, egy itifo*adre»oreeepfor blokkoló, agy atmboHkus szteroid, ggy szorongás élietii szer, egy pszichózis elleni szer, egy aótíÓepresszáBS. egy bétay2 agonistaiegy sntikoimefg hörgóíágHó. ieoítiíin, amínofüUn. nedoksoswi-nâtrumi, nátrium- kronroglikát, egy kíikööMk receptor amagonista, egy köptető, egy slefmoldó szer. egy itat tkí sziámin, pSze?«íöéfodrin, egy neuraínioidáz inhibitor, Bctagtm® Betimoi*. Timoptlc*, Betöpttc^k^aptesi55, Opttpranokií®, Xalatan*, Àlphagan*, Azopt®, Trusopt® Cosopt®, Pilocar*’, kilagan®, Propine®, Opttemm*, Acutar*', Uvostín*, Alomide®, Emseimé®, Patanol*, Aires®, Dexaeidin®, Maxiiról®, Tebradex®, Eiieplmmide®, Oeufen®. Voltaren®, -ProdkfibSi?*» IfoMpred Phis®, iífopgr, Flarex* Mamasa Pori#, ítrflamase Mild®, Lotema#, Vexol®, PÓÍytrini®, flolyeitr, öíoxan* OeuBox®, Tobrex® vagy Garamycin®, vagy ezek tetszőleges kombinációja.
- 5. Kompozíció, arneiy magában foglal egy t. igénypont szerinti vegyük tét vagy címek egy optikai izo-merjél vagy ezek egy győgyáSzsrilág elfogadható sóját vagy ezek tetszőleges kombinációját, gyógyszerként való sikahTtazásra, 6 Kompozíció, amely magában foglal egy !. igénypont szerinti vegybieteí vagy ennék: egy optikai izo* meijét vagy ezek egy gyúgyászáíilág elfogadható sóját vagy ezek tetsző leges zások valamelyikére: fogamzásgátlásra egy Mnr egyeditek htutttöttterápiára egy andrögétt-íiiggő; állapotban; proSZtatta'ákbaii szenvedő egyed kezelésére; prosztatarák e löreha 1 adásának kési e iteiéMre : @gy éSOíntíti fotpésoiálosskóros reodéllánesség kezpiéséte. vagy a esöfiitütpeg növelésére vagy esoíttkép-zodés elősegítésére; jzpUjsorvádÓsos rendellenesség kezelésére, előfordulási gyakoriságának csökkentésére, xáiyösságániik; csökkentésére vagy a véle együtt járó tünetek enyhítésére; Cukőrbetegség, gíükőz intoleraneía. fokozott vérrazuHn-tükör, inzulitfereziszíetteia, cukorbetegséggel együtt járó betegségek, xririüáya! együtt járó állapotok, kardiovaszkniáris megbetegedés vagy setiyvedtség kezelésére, súlyosságának' csökkentésére, előfordulási gyakoriságának csökkentésére, kialakulásának késleltetésére vagy kót tcjlödesénekikésíelfotésére ; á szem egy betegségének vagy kóros állapotánakkéketésére; aízsitfomeg csökkentésére; vagy a sovány tömeg növelésére. ?. Kompozíció a ő. igénypont szerinti alkalmazásra, altul ti csonttá? kapcsolatos rcsK-eiícncsség csontritkulás, oszteopeniu, megoővékódeft csontlebomlás, csöiitfofés, csonttörekeíiység, a csent ásványi sűrűségének (HMD) csökkenése vagy ezektstszöleps kombinációja, a vap a készftmëny növeli a csőig erössdpk serkáíííi vagy iökozza a csontszqveiképzddési vagy gátolja g:'Os^^tefvàpi:t^âé^t.
- 9, Kompozíció a 6. igénypofii szerinti álkálma^Sras ahol m izomsorvadíBös rtmíiélleoesség o^'$ patológia, msgbeícgeüvi. betegség vagy kóros állapi. 1(5, KPjnpotdció a 9, igénypont s^eíitít t ïtlkiti ni áfásra, ahol a pgíolijgia, átegbetepdés,i>öiegság vasgyár .itS'iifepöt a«mtíógiai,.fertŐSíéses,..kíófll^t'Ví||^' geneitkat erettelíl
- 11, Kompaîicid s 9; vagy 10. igéttyptttm»rinti alkainiíigásrá,: ahol a patológia, megbetegedés, betepög vagy kóros állapot ízöaidísKtröfia, ízmiiaíröíia, X-kronmszomáíis gefisovélö^nyaitveld feoitmtré£l& (SBMA)s sehyyediáág. átiíMplálság, lepra, cukorbetegség, vésebetegség, krónikus elzárödásos íüdöfeeiegsóg (€01¾ rák, végállapot« veseelégteienscg., szarkopsnia, köibszöveú gáz.gyülem, csontlágvulás, H.lV-fö«özés, ΛΠ>$ vagy szivizombetegség. 12. K. Kompozíció a II. igénypont szerinti alkalmazásra, abol az izomdísziTóla Duchenne féle ízömdisztróiaj Beckor féle immdisztroíia vagy iniotôptâÿ dlsgôiOfc
- 13. Kompozíció a ö. igénypont szerinti alkalmazásra, ahol az izomsorvadihos rendellenesség korral ösz~ szeíuggÖ az izomsorvadásos rendellenesség vagy oíyám tj5ô«^kÂ^?'ï§B#eltsne§si|^ .jroeíynefc.ö^ÍÉróoikus báttajáa, égési sérülések, a központi Idegrendszer (CHS) sérülése vagy károsodása, perifériális idegsérülés vagy -károsodÉ,, geftncvólö-sérüiés vagy -korosodás, yë^s^ro|;.ÂÂiitl^,:^«Îi8ié8U -séH«é&*agy MrosaÄ vagy alkoholizmus.
- 14, Kompozíció a 6, igénypont szerinti allcáimazásráj Érni a szem betegsége vagy kötos állapota a SjÖgfépfsélSá^roa: 'vz^msM&'&xmág,
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83966506P | 2006-08-24 | 2006-08-24 | |
PCT/US2006/033490 WO2007027582A2 (en) | 2005-08-31 | 2006-08-28 | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators |
US11/510,844 US20070066568A1 (en) | 2005-08-31 | 2006-08-28 | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators |
US90774907P | 2007-04-16 | 2007-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE029808T2 true HUE029808T2 (hu) | 2017-03-28 |
Family
ID=48170081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE07837277A HUE029808T2 (hu) | 2006-08-24 | 2007-08-24 | Szubsztituált acilanilid-származékok és az alkalmazásukra szolgáló eljárások |
Country Status (19)
Country | Link |
---|---|
US (3) | US8080682B2 (hu) |
EP (2) | EP2054049B1 (hu) |
JP (2) | JP5345534B2 (hu) |
KR (2) | KR101264820B1 (hu) |
CN (3) | CN107007581A (hu) |
AR (1) | AR062536A1 (hu) |
AU (1) | AU2007287070C1 (hu) |
BR (1) | BRPI0714526A2 (hu) |
CA (1) | CA2660570C (hu) |
CY (1) | CY1117817T1 (hu) |
DK (1) | DK2054049T3 (hu) |
EA (1) | EA016853B1 (hu) |
ES (1) | ES2581765T3 (hu) |
HU (1) | HUE029808T2 (hu) |
IL (3) | IL197185A (hu) |
MX (1) | MX2009001962A (hu) |
PL (1) | PL2054049T3 (hu) |
PT (1) | PT2054049E (hu) |
WO (1) | WO2008024456A2 (hu) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8445534B2 (en) * | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US8309603B2 (en) * | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
WO2007027582A2 (en) * | 2005-08-31 | 2007-03-08 | University Of Tennessee Research Foundation | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
PT2054049E (pt) | 2006-08-24 | 2016-06-02 | Univ Tennessee Res Found | Acilanilidas substituídas e métodos de utilização das mesmas |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
AU2009215843B2 (en) | 2008-02-22 | 2011-09-08 | Ellipses Pharma Ltd | Selective androgen receptor modulators |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
ES2530723T3 (es) | 2008-05-07 | 2015-03-04 | Univ California | Reposición y enriquecimiento terapéuticos de la lubricación de la superficie ocular |
US8506944B2 (en) * | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
WO2010027743A1 (en) * | 2008-08-25 | 2010-03-11 | Alpha Synergy Development, Inc. | Pharmaceutical compositions and methods for the treatment of dry eye |
WO2010056979A1 (en) * | 2008-11-14 | 2010-05-20 | Immune Control, Inc. | Phenothiazine derivatives for treatment of asthma |
US8815280B2 (en) | 2008-12-09 | 2014-08-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US11173167B2 (en) | 2008-12-09 | 2021-11-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9539224B2 (en) | 2008-12-09 | 2017-01-10 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9707241B2 (en) | 2008-12-09 | 2017-07-18 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9259430B2 (en) | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US8870876B2 (en) * | 2009-02-13 | 2014-10-28 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
EP2405906A4 (en) * | 2009-03-12 | 2012-10-17 | Viridis Biopharma Pvt Ltd | METHOD OF USING VITAMIN K AS AN ENERGY STIMULATOR IN VARIOUS CONDITIONS OF DISEASE |
US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
ES2688447T3 (es) | 2009-10-09 | 2018-11-02 | Nestec S.A. | Métodos para prevenir o tratar la sarcopenia y la atrofia muscular en animales |
EP2523556A4 (en) * | 2010-01-11 | 2013-08-28 | Gtx Inc | METHOD FOR TREATING MIBROMED DYNAMIC FUNCTION |
US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
EP2531029B1 (en) | 2010-02-04 | 2016-10-19 | Radius Health, Inc. | Selective androgen receptor modulators |
AU2015200324C1 (en) * | 2010-03-23 | 2016-12-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
EP3106159A1 (en) | 2010-05-12 | 2016-12-21 | Radius Health, Inc. | Therapeutic regimens |
US8696719B2 (en) | 2010-06-03 | 2014-04-15 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2012047617A1 (en) | 2010-09-28 | 2012-04-12 | Radius Health, Inc. | Selective androgen receptor modulators |
KR101875705B1 (ko) | 2011-12-07 | 2018-07-06 | 삼성전자주식회사 | 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물 |
KR20130063962A (ko) * | 2011-12-07 | 2013-06-17 | 가천대학교 산학협력단 | 디아미노디페닐술폰을 포함하는 골량 저하 질환의 예방 또는 치료용 약학적 조성물 |
US20150071857A1 (en) * | 2012-03-07 | 2015-03-12 | Ligand Pharmaceuticals, Inc. | Steroid hormone and cholesterol pathways as one unified homeostatic system |
ES2624250T3 (es) * | 2012-05-09 | 2017-07-13 | Icrom Spa | Producción de brinzolamida farmacéutica estéril |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
CN108143728A (zh) | 2012-07-13 | 2018-06-12 | Gtx公司 | 选择性雄激素受体调节剂在治疗乳癌中的用途 |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
WO2014037811A2 (en) | 2012-09-07 | 2014-03-13 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
WO2014144907A1 (en) * | 2013-03-15 | 2014-09-18 | Children's Medical Center Corporation | Methods and compounds for the treatment of dystroglycanopathies |
WO2015061724A1 (en) * | 2013-10-24 | 2015-04-30 | University Of Tennesse Research Foundation | Selective androgen receptor modulator and chemotherapeutic agent for treating muscle wasting in cancer patients |
CA2943611A1 (en) | 2014-03-28 | 2015-10-01 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
JP7019422B2 (ja) | 2015-04-29 | 2022-02-15 | ラジウス ファーマシューティカルズ,インコーポレイテッド | 癌を治療するための方法 |
AU2016323779B2 (en) | 2015-09-16 | 2022-03-17 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
SG11201811225RA (en) | 2016-06-22 | 2019-01-30 | Radius Health Inc | Ar+ breast cancer treatment methods |
JP2020500198A (ja) * | 2016-11-17 | 2020-01-09 | サイトーCytoo | 骨格筋肥大誘発剤 |
CN106748884B (zh) * | 2016-12-13 | 2021-08-20 | 山西振东制药股份有限公司 | 一种比卡鲁胺中间体的制备方法 |
KR102557321B1 (ko) | 2017-01-05 | 2023-07-18 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
JP7207308B2 (ja) * | 2017-08-03 | 2023-01-18 | ソニーグループ株式会社 | コンタクトレンズおよび検出方法 |
SG11202013177WA (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
CN109207724B (zh) * | 2018-09-12 | 2020-12-29 | 哈尔滨工业大学(威海) | 一种从含钒铬溶液中同时萃取分离钒铬的萃取溶剂及萃取方法 |
CN109761778A (zh) * | 2018-12-10 | 2019-05-17 | 石家庄市度智医药科技有限公司 | 一种合成光学活性α-羟基丙酰胺衍生物的方法 |
CN111418558B (zh) * | 2019-09-22 | 2021-09-28 | 山西大学 | 一种消融代谢性泌尿结石动物模型的构建方法 |
AU2021213297A1 (en) * | 2020-01-27 | 2022-08-18 | Eirgen Pharma Ltd. | Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease |
WO2023215684A1 (en) * | 2022-05-05 | 2023-11-09 | The Trustees Of Indiana University | Therapeutic strategies to manage facial contractures post injury |
CN114796496B (zh) * | 2022-05-09 | 2023-06-23 | 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) | 交感神经活化抑制剂和/或α1-肾上腺素能受体抑制剂在制备治疗干眼症的药物中的应用 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3256096A (en) | 1961-08-11 | 1966-06-14 | Organic Nutrients Inc | Anabolic stimulator as a poultry feed supplement |
US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
US3949085A (en) | 1970-05-27 | 1976-04-06 | Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt | Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
GB1360001A (en) | 1971-06-16 | 1974-07-17 | Scherico Ltd | Pharmaceutical compositions comprising substituted anilides |
US3875229A (en) * | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
US3865801A (en) | 1973-06-15 | 1975-02-11 | Atomic Energy Commission | Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol |
US3946109A (en) | 1973-08-08 | 1976-03-23 | Ernst Kolb | Animal feed composition containing certain vitamin combinations |
US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
US4211781A (en) | 1974-09-23 | 1980-07-08 | Pfizer Inc. | Process for the preparation of dustless quinoxaline-1,4-dioxide animal feed supplement premixes |
US3991750A (en) | 1975-04-28 | 1976-11-16 | Syntex Corporation | Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals |
JPS6044294B2 (ja) | 1976-04-15 | 1985-10-02 | 帝国臓器製薬株式会社 | アニリド誘導体 |
US4139638A (en) * | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
EP0002309B1 (en) | 1977-10-12 | 1982-12-01 | Imperial Chemical Industries Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
US4191775A (en) * | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
US4447421A (en) | 1980-05-08 | 1984-05-08 | American Cyanamid Company | Process for the preparation of medicated animal feed supplement |
NZ197008A (en) * | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
JPS57171904A (en) * | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
EP0100172B1 (en) * | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
FR2576025B1 (fr) | 1985-01-14 | 1987-01-23 | Roussel Uclaf | Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant |
US4670249A (en) | 1985-04-12 | 1987-06-02 | International Minerals & Chemical Corp. | Growth-promoting compositions |
US4837004A (en) | 1985-10-18 | 1989-06-06 | Eastman Kodak Company | Rumen-stable pellets |
US4904473A (en) | 1986-06-23 | 1990-02-27 | International Minerals & Chemical Corp. | Ruminant feed antacid containing potassium, sodium and chlorine |
GB8617652D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
GB8617653D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
US4849447A (en) | 1987-10-13 | 1989-07-18 | Pitman-Moore, Inc. | Zearalanol derivatives with anabolic activity |
EP0398961B1 (en) | 1988-01-28 | 1994-11-02 | Polygen Holding Corporation | Polypeptide compounds having growth hormone releasing activity |
DE68922602T2 (de) | 1988-01-28 | 1995-12-07 | Polygen Holding Corp | Polypeptide mit hormonwachstumsbefreiender wirkung. |
US4977288A (en) * | 1988-01-29 | 1990-12-11 | President And Fellows Of Harvard College | M-aminophenyltrialkylstannane |
US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US5179080A (en) | 1989-08-31 | 1993-01-12 | Clinical Homecare, Corp. | Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease |
AU646822B2 (en) | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
US5030657A (en) | 1989-10-23 | 1991-07-09 | University Of Georgia Research Foundation, Inc. | L-carnitine supplemented catfish diet |
US5288496A (en) | 1990-05-15 | 1994-02-22 | Stolle Research & Development Corporation | Growth promoters for animals |
US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
CA2181358A1 (en) | 1994-01-21 | 1995-07-27 | Nancy M. Gray | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
US5609849A (en) * | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
DE69500542T2 (de) | 1994-05-19 | 1998-01-02 | Akzo Nobel Nv | 11,21-Bisphenyl-19-nor-pregnan Derivate |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
WO1998005962A1 (en) | 1996-08-02 | 1998-02-12 | Panvera Corporation | A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization |
US20050038110A1 (en) * | 2000-08-24 | 2005-02-17 | Steiner Mitchell S. | Selective androgen receptor modulators and methods of use thereof |
US6492554B2 (en) * | 2000-08-24 | 2002-12-10 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
US6995284B2 (en) | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US5929058A (en) | 1996-12-24 | 1999-07-27 | Zymogenetics, Inc. | Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
AU7604798A (en) * | 1997-05-30 | 1998-12-30 | University Of Tennessee Research Corporation, The | Non-steroidal agonist compounds and their use in male hormone therapy |
AU7723198A (en) * | 1997-06-04 | 1998-12-21 | University Of Tennessee Research Corporation, The | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
EP0903146A1 (en) | 1997-09-23 | 1999-03-24 | Applied Research Systems ARS Holdings N.V. | 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid |
US6022137A (en) | 1998-04-29 | 2000-02-08 | Buckeye Feed Mills, Inc. | Conditioner for processing raw grain composition to produce pelletized feed |
US6489366B1 (en) | 1998-12-23 | 2002-12-03 | G. D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
MXPA01009814A (es) | 1999-03-29 | 2002-04-24 | Hoffmann La Roche | Activadores de la glucoquinasa. |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
WO2001027622A1 (en) | 1999-10-14 | 2001-04-19 | Bristol-Myers Squibb Company | Crystallographic structure of the androgen receptor ligand binding domain |
US6583306B1 (en) | 1999-10-19 | 2003-06-24 | Nobex Corporation | Methods of asymmetrically synthesizing enantiomers of Casodex, its derivatives and intermediates thereof |
AU2619501A (en) | 1999-10-27 | 2001-06-06 | Nobex Corporation | Resolution of intermediates in the synthesis of substantially pure bicalutamide |
US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
AU2625201A (en) | 2000-01-03 | 2001-07-16 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Glycogen synthase kinase-3 inhibitors |
US6441197B1 (en) * | 2000-01-20 | 2002-08-27 | Daiichi Pure Chemicals Co., Ltd. | Diaminofluorescein derivative |
US7713989B2 (en) | 2000-04-27 | 2010-05-11 | Dow Robert L | Glucocorticoid receptor modulators |
IL152719A0 (en) | 2000-06-28 | 2003-06-24 | Bristol Myers Squibb Co | Selective androgen receptor modulators and methods for their identification |
JP2002035743A (ja) * | 2000-07-21 | 2002-02-05 | Kurita Water Ind Ltd | 軟水装置 |
US20020173495A1 (en) * | 2000-08-24 | 2002-11-21 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
US6838484B2 (en) * | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
PT1401801E (pt) | 2000-08-24 | 2007-02-28 | Univ Tennessee Res Foundation | Modulares selectivos de receptor de androgénio e métodos para a sua utilização |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US20030232792A1 (en) | 2000-08-24 | 2003-12-18 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
US6998500B2 (en) * | 2000-08-24 | 2006-02-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
AU2002364949C1 (en) * | 2001-12-06 | 2008-05-29 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
JP4368683B2 (ja) | 2002-02-01 | 2009-11-18 | メルク エンド カムパニー インコーポレーテッド | 糖尿病、肥満症および脂質代謝異常の治療に有用な11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1阻害剤 |
ATE518537T1 (de) | 2002-02-07 | 2011-08-15 | Univ Tennessee Res Foundation | Selective androgen-rezeptor-modulatoren (sarms) für die behandlung der benignen prostatahyperplasie |
US7344700B2 (en) | 2002-02-28 | 2008-03-18 | University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
US7705182B2 (en) * | 2002-02-28 | 2010-04-27 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
AU2003217303A1 (en) | 2002-02-28 | 2003-09-16 | University Of Tennessee Research Foundation | Haloacetamide and azide substituted compounds and methods of use thereof |
AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
US20040087810A1 (en) | 2002-10-23 | 2004-05-06 | Dalton James T. | Irreversible selective androgen receptor modulators and methods of use thereof |
US8309603B2 (en) * | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
WO2004060146A2 (en) | 2002-12-30 | 2004-07-22 | Purdue Research Foundation | Method of treatment for central nervous system injury |
EP1594490A4 (en) * | 2003-01-22 | 2006-03-22 | Gtx Inc | TREATMENT OF WOMEN ANDROGEN DISEASE ASSOCIATED DISORDERS (ADIF) USING ANDROGENIC RECEPTOR MODULATORS (SARM) |
GB0308335D0 (en) | 2003-04-10 | 2003-05-14 | Novartis Ag | Organic compounds |
PT1696909E (pt) | 2003-09-12 | 2007-12-21 | Serono Lab | Derivados benzotiazolo para o tratamento de diabetes |
JP2007508386A (ja) | 2003-10-14 | 2007-04-05 | ジーティーエックス・インコーポレイテッド | 選択的アンドロゲン受容体調節剤による骨関連疾患の治療 |
GB0325402D0 (en) | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
PL1756096T3 (pl) | 2004-05-03 | 2010-01-29 | Hoffmann La Roche | Pochodne indolilowe jako modulatory wątrobowych receptorów X |
PL1753417T3 (pl) | 2004-06-07 | 2012-09-28 | Univ Tennessee Res Found | Selektywny modulator receptora androgenowego i jego zastosowania medyczne |
EA200700262A1 (ru) | 2004-07-14 | 2007-08-31 | Янссен Фармацевтика Н.В. | Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа |
WO2006011141A2 (en) | 2004-07-25 | 2006-02-02 | Israel Aerospace Industries Ltd. | Method and system for the acquisition of data and for the display of data |
WO2007027582A2 (en) | 2005-08-31 | 2007-03-08 | University Of Tennessee Research Foundation | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators |
EP1951706A1 (en) | 2005-11-01 | 2008-08-06 | Janssen Pharmaceutica N.V. | Dihydroisoindolones as allosteric modulators of glucokinase |
JP2009513704A (ja) | 2005-11-01 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グルコキナーゼのアロステリックモジュレーターとしての置換ジヒドロイソインドロン |
WO2007075702A2 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
PT2054049E (pt) * | 2006-08-24 | 2016-06-02 | Univ Tennessee Res Found | Acilanilidas substituídas e métodos de utilização das mesmas |
EP2523556A4 (en) * | 2010-01-11 | 2013-08-28 | Gtx Inc | METHOD FOR TREATING MIBROMED DYNAMIC FUNCTION |
-
2007
- 2007-08-24 PT PT07837277T patent/PT2054049E/pt unknown
- 2007-08-24 EP EP07837277.8A patent/EP2054049B1/en active Active
- 2007-08-24 KR KR1020117014249A patent/KR101264820B1/ko active IP Right Grant
- 2007-08-24 DK DK07837277.8T patent/DK2054049T3/en active
- 2007-08-24 PL PL07837277.8T patent/PL2054049T3/pl unknown
- 2007-08-24 CN CN201610836622.7A patent/CN107007581A/zh active Pending
- 2007-08-24 US US11/892,595 patent/US8080682B2/en not_active Expired - Fee Related
- 2007-08-24 BR BRPI0714526-8A patent/BRPI0714526A2/pt not_active Application Discontinuation
- 2007-08-24 JP JP2009525637A patent/JP5345534B2/ja not_active Expired - Fee Related
- 2007-08-24 WO PCT/US2007/018686 patent/WO2008024456A2/en active Application Filing
- 2007-08-24 AU AU2007287070A patent/AU2007287070C1/en not_active Ceased
- 2007-08-24 MX MX2009001962A patent/MX2009001962A/es active IP Right Grant
- 2007-08-24 HU HUE07837277A patent/HUE029808T2/hu unknown
- 2007-08-24 CA CA2660570A patent/CA2660570C/en not_active Expired - Fee Related
- 2007-08-24 EP EP16158958.5A patent/EP3056483A1/en not_active Withdrawn
- 2007-08-24 EA EA200900345A patent/EA016853B1/ru not_active IP Right Cessation
- 2007-08-24 ES ES07837277.8T patent/ES2581765T3/es active Active
- 2007-08-24 KR KR1020097005629A patent/KR101202240B1/ko active IP Right Grant
- 2007-08-24 CN CN201310162641.2A patent/CN103251579B/zh not_active Expired - Fee Related
- 2007-08-24 CN CN2007800396488A patent/CN101528214B/zh not_active Expired - Fee Related
- 2007-08-27 AR ARP070103786A patent/AR062536A1/es active IP Right Grant
-
2009
- 2009-02-23 IL IL197185A patent/IL197185A/en active IP Right Grant
-
2011
- 2011-11-22 US US13/302,988 patent/US8426465B2/en not_active Expired - Fee Related
-
2013
- 2013-04-04 JP JP2013078332A patent/JP5745560B2/ja not_active Expired - Fee Related
- 2013-04-23 US US13/868,768 patent/US8846756B2/en not_active Expired - Fee Related
-
2014
- 2014-01-30 IL IL230759A patent/IL230759A/en active IP Right Grant
-
2016
- 2016-03-03 IL IL244442A patent/IL244442B/en active IP Right Grant
- 2016-07-12 CY CY20161100656T patent/CY1117817T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2054049T3 (en) | SUBSTITUTED ACYLANILIDES AND PROCEDURES FOR USING THEREOF | |
CA2658394C (en) | Substituted acylanilides and methods of use thereof | |
US7772433B2 (en) | SARMS and method of use thereof | |
US20130034562A1 (en) | Selective androgen receptor modulators for treating diabetes | |
US20180071242A1 (en) | Substituted acylanilides and methods of use thereof | |
US20140011774A1 (en) | Selective androgen receptor modulators | |
IL201352A (en) | Use of (n) (n) (4-cyano-3-trifluoromethyl) phenyl) -3- (4-cyanophenoxy) -2-hydroxy-2 methylpropanamide for the preparation of a drug for the treatment of glucose intolerance, hyperinsulinemia and insulin resistance: s) –n– (4– cyano – 3 – trifluoromethyl) phenyl) –3– (4 – cyanophenoxy) –2 hydroxy – 2– methylpropanamide with drug | |
US9889110B2 (en) | Selective androgen receptor modulator for treating hormone-related conditions | |
WO2015061724A1 (en) | Selective androgen receptor modulator and chemotherapeutic agent for treating muscle wasting in cancer patients | |
US20190055192A1 (en) | Selective androgen receptor modulator and methods of use thereof | |
AU2013200516B2 (en) | Substituted Acylanilides and Methods of Use Thereof | |
US10662148B2 (en) | Selective androgen receptor modulator and methods of use thereof | |
AU2015264895B2 (en) | Substituted Acylanilides and Methods of Use Thereof |